Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE

Roberto de Marco, Alessandro Marcon, Deborah Jarvis, Simone Accordini, Massimiliano Bugiani, Lucia Cazzoletti, Isa Cerveri, Angelo Corsico, David Gislason, Amund Gulsvik, Rain Jõgi, Jesús Martínez-Moratalla, Isabelle Pin, Christer Janson

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Few studies have investigated the long-term association between inhaled corticosteroids (ICSs) and lung function decline in asthma. Objective: To evaluate whether prolonged treatment with ICSs is associated with FEV1 decline in adults with asthma. Methods: An international cohort of 667 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1999 to 2002. Spirometry was performed on both occasions. FEV1 decline was analyzed according to age, sex, height, body mass index, total IgE, time of ICS use, and smoking, while adjusting for potential confounders. Results: As ICS use increased, the decline in FEV1 was lower (P trend = .025): on average, decline passed from 34 mL/y in nonusers (half of the sample) to 20 mL/y in subjects treated for 48 months or more (18%). When adjusting for all covariates, there was an interaction (P = .02) between ICS use and total IgE: in subjects with high (>100 kU/L) IgE, ICS use for 4 years or more was associated with a lower FEV1 decline (23 mL/y; 95% CI, 8-38 compared with nonusers). This association was not seen in those with lower IgE. Conclusion: Although confirming a beneficial long-term association between ICSs and lung function in asthma, our study suggests that subjects with high IgE could maximally benefit from a prolonged ICS treatment. Clinical implications: This study adds further evidence to the beneficial effect of inhaled steroids on lung function in asthma; future studies will clarify whether calibrating the corticosteroid dose according to the level of total IgE is a feasible approach in asthma management.

Original languageEnglish
Pages (from-to)611-617
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume119
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Immunoglobulin E
Adrenal Cortex Hormones
Asthma
Steroids
Lung
Spirometry
European Union
Health Surveys
Body Mass Index
Smoking

Keywords

  • Asthma
  • ECRHS
  • eosinophils
  • European Community Respiratory Health Survey
  • FEV decline
  • inhaled corticosteroids
  • lung function decline
  • prospective cohort study
  • total IgE

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. / de Marco, Roberto; Marcon, Alessandro; Jarvis, Deborah; Accordini, Simone; Bugiani, Massimiliano; Cazzoletti, Lucia; Cerveri, Isa; Corsico, Angelo; Gislason, David; Gulsvik, Amund; Jõgi, Rain; Martínez-Moratalla, Jesús; Pin, Isabelle; Janson, Christer.

In: Journal of Allergy and Clinical Immunology, Vol. 119, No. 3, 03.2007, p. 611-617.

Research output: Contribution to journalArticle

de Marco, R, Marcon, A, Jarvis, D, Accordini, S, Bugiani, M, Cazzoletti, L, Cerveri, I, Corsico, A, Gislason, D, Gulsvik, A, Jõgi, R, Martínez-Moratalla, J, Pin, I & Janson, C 2007, 'Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE', Journal of Allergy and Clinical Immunology, vol. 119, no. 3, pp. 611-617. https://doi.org/10.1016/j.jaci.2006.11.696
de Marco, Roberto ; Marcon, Alessandro ; Jarvis, Deborah ; Accordini, Simone ; Bugiani, Massimiliano ; Cazzoletti, Lucia ; Cerveri, Isa ; Corsico, Angelo ; Gislason, David ; Gulsvik, Amund ; Jõgi, Rain ; Martínez-Moratalla, Jesús ; Pin, Isabelle ; Janson, Christer. / Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. In: Journal of Allergy and Clinical Immunology. 2007 ; Vol. 119, No. 3. pp. 611-617.
@article{380fe1eb7a824fa3855b7c986793c4e9,
title = "Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE",
abstract = "Background: Few studies have investigated the long-term association between inhaled corticosteroids (ICSs) and lung function decline in asthma. Objective: To evaluate whether prolonged treatment with ICSs is associated with FEV1 decline in adults with asthma. Methods: An international cohort of 667 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1999 to 2002. Spirometry was performed on both occasions. FEV1 decline was analyzed according to age, sex, height, body mass index, total IgE, time of ICS use, and smoking, while adjusting for potential confounders. Results: As ICS use increased, the decline in FEV1 was lower (P trend = .025): on average, decline passed from 34 mL/y in nonusers (half of the sample) to 20 mL/y in subjects treated for 48 months or more (18{\%}). When adjusting for all covariates, there was an interaction (P = .02) between ICS use and total IgE: in subjects with high (>100 kU/L) IgE, ICS use for 4 years or more was associated with a lower FEV1 decline (23 mL/y; 95{\%} CI, 8-38 compared with nonusers). This association was not seen in those with lower IgE. Conclusion: Although confirming a beneficial long-term association between ICSs and lung function in asthma, our study suggests that subjects with high IgE could maximally benefit from a prolonged ICS treatment. Clinical implications: This study adds further evidence to the beneficial effect of inhaled steroids on lung function in asthma; future studies will clarify whether calibrating the corticosteroid dose according to the level of total IgE is a feasible approach in asthma management.",
keywords = "Asthma, ECRHS, eosinophils, European Community Respiratory Health Survey, FEV decline, inhaled corticosteroids, lung function decline, prospective cohort study, total IgE",
author = "{de Marco}, Roberto and Alessandro Marcon and Deborah Jarvis and Simone Accordini and Massimiliano Bugiani and Lucia Cazzoletti and Isa Cerveri and Angelo Corsico and David Gislason and Amund Gulsvik and Rain J{\~o}gi and Jes{\'u}s Mart{\'i}nez-Moratalla and Isabelle Pin and Christer Janson",
year = "2007",
month = "3",
doi = "10.1016/j.jaci.2006.11.696",
language = "English",
volume = "119",
pages = "611--617",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE

AU - de Marco, Roberto

AU - Marcon, Alessandro

AU - Jarvis, Deborah

AU - Accordini, Simone

AU - Bugiani, Massimiliano

AU - Cazzoletti, Lucia

AU - Cerveri, Isa

AU - Corsico, Angelo

AU - Gislason, David

AU - Gulsvik, Amund

AU - Jõgi, Rain

AU - Martínez-Moratalla, Jesús

AU - Pin, Isabelle

AU - Janson, Christer

PY - 2007/3

Y1 - 2007/3

N2 - Background: Few studies have investigated the long-term association between inhaled corticosteroids (ICSs) and lung function decline in asthma. Objective: To evaluate whether prolonged treatment with ICSs is associated with FEV1 decline in adults with asthma. Methods: An international cohort of 667 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1999 to 2002. Spirometry was performed on both occasions. FEV1 decline was analyzed according to age, sex, height, body mass index, total IgE, time of ICS use, and smoking, while adjusting for potential confounders. Results: As ICS use increased, the decline in FEV1 was lower (P trend = .025): on average, decline passed from 34 mL/y in nonusers (half of the sample) to 20 mL/y in subjects treated for 48 months or more (18%). When adjusting for all covariates, there was an interaction (P = .02) between ICS use and total IgE: in subjects with high (>100 kU/L) IgE, ICS use for 4 years or more was associated with a lower FEV1 decline (23 mL/y; 95% CI, 8-38 compared with nonusers). This association was not seen in those with lower IgE. Conclusion: Although confirming a beneficial long-term association between ICSs and lung function in asthma, our study suggests that subjects with high IgE could maximally benefit from a prolonged ICS treatment. Clinical implications: This study adds further evidence to the beneficial effect of inhaled steroids on lung function in asthma; future studies will clarify whether calibrating the corticosteroid dose according to the level of total IgE is a feasible approach in asthma management.

AB - Background: Few studies have investigated the long-term association between inhaled corticosteroids (ICSs) and lung function decline in asthma. Objective: To evaluate whether prolonged treatment with ICSs is associated with FEV1 decline in adults with asthma. Methods: An international cohort of 667 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1999 to 2002. Spirometry was performed on both occasions. FEV1 decline was analyzed according to age, sex, height, body mass index, total IgE, time of ICS use, and smoking, while adjusting for potential confounders. Results: As ICS use increased, the decline in FEV1 was lower (P trend = .025): on average, decline passed from 34 mL/y in nonusers (half of the sample) to 20 mL/y in subjects treated for 48 months or more (18%). When adjusting for all covariates, there was an interaction (P = .02) between ICS use and total IgE: in subjects with high (>100 kU/L) IgE, ICS use for 4 years or more was associated with a lower FEV1 decline (23 mL/y; 95% CI, 8-38 compared with nonusers). This association was not seen in those with lower IgE. Conclusion: Although confirming a beneficial long-term association between ICSs and lung function in asthma, our study suggests that subjects with high IgE could maximally benefit from a prolonged ICS treatment. Clinical implications: This study adds further evidence to the beneficial effect of inhaled steroids on lung function in asthma; future studies will clarify whether calibrating the corticosteroid dose according to the level of total IgE is a feasible approach in asthma management.

KW - Asthma

KW - ECRHS

KW - eosinophils

KW - European Community Respiratory Health Survey

KW - FEV decline

KW - inhaled corticosteroids

KW - lung function decline

KW - prospective cohort study

KW - total IgE

UR - http://www.scopus.com/inward/record.url?scp=33847246296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847246296&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2006.11.696

DO - 10.1016/j.jaci.2006.11.696

M3 - Article

VL - 119

SP - 611

EP - 617

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -